Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Non-Current Assets: 2010-2025

Historic Non-Current Assets for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $434.7 million.

  • Arrowhead Pharmaceuticals' Non-Current Assets fell 2.18% to $434.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $434.7 million, marking a year-over-year decrease of 2.18%. This contributed to the annual value of $434.7 million for FY2025, which is 2.18% down from last year.
  • According to the latest figures from FY2025, Arrowhead Pharmaceuticals' Non-Current Assets is $434.7 million, which was down 2.18% from $444.3 million recorded in FY2024.
  • Arrowhead Pharmaceuticals' Non-Current Assets' 5-year high stood at $444.3 million during FY2024, with a 5-year trough of $286.6 million in FY2022.
  • Its 3-year average for Non-Current Assets is $409.4 million, with a median of $434.7 million in 2025.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Non-Current Assets skyrocketed by 62.67% in 2021, and later fell by 11.95% in 2022.
  • Yearly analysis of 5 years shows Arrowhead Pharmaceuticals' Non-Current Assets stood at $325.6 million in 2021, then fell by 11.95% to $286.6 million in 2022, then grew by 21.78% to $349.1 million in 2023, then climbed by 27.29% to $444.3 million in 2024, then dropped by 2.18% to $434.7 million in 2025.